Details of the Drug Combinations

General Information of This Drug (ID: DMHSY1I)

• Drug Name: Regorafenib (DMHSY1I)
• Synonyms: Regorafenib; 755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]

Indication

Gastrointestinal stromal tumour; ICD 11: 2B5B; Status: Approved [1]; Metastasis from malignant tumor of colon; ICD 11: N.A.; Status: Approved [1]; Metastatic colorectal cancer; ICD 11: 2B91; Status: Approved [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

24 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Napabucasin + Regorafenib	DCUBM47	Napabucasin	Advanced Gastrointestinal Cancer	[3]
Omeprazole + Regorafenib	DCHWZY8	Omeprazole	Neoplasms	[4]
Regorafenib + Rosiglitazone	DCVH0P6	Rosiglitazone	Neoplasms	[4]
Regorafenib + Oxaliplatin	DC2UKR6	Oxaliplatin	Metastatic Colorectal Cancer	[5]
Regorafenib + Vincristine	DC6NGTV	Vincristine	Pediatric Oncology	[6]
Regorafenib + Vincristine	DCY85D6	Vincristine	Rhabdomyosarcoma	[7]
Regorafenib + Oxaliplatin	DC3TQFP	Oxaliplatin	Digestive Cancer	[8]
Regorafenib + Raltitrexed	DC5BAEO	Raltitrexed	Regorafenib	[9]
Regorafenib + Bay 86-9766	DCJG7WO	Bay 86-9766	Neoplasms	[10]
Regorafenib + Capecitabine	DCNQWSH	Capecitabine	Rectal Cancer	[11]
Regorafenib + Rosuvastatin	DCSV7DS	Rosuvastatin	Neoplasms	[12]
Regorafenib + Temozolomide	DCUREOP	Temozolomide	Glioblastoma, IDH-wildtype	[13]
Regorafenib + Digoxin	DCX2L72	Digoxin	Neoplasms	[12]
Sunitinib + Regorafenib	DC0I3EK	Sunitinib	Gastrointestinal Stromal Tumor	[14]
Fulvestrant + Regorafenib	DCGVKYC	Fulvestrant	Ovarian Cancer	[15]
Regorafenib + Cabozantinib	DCY6J0F	Cabozantinib	Non-small Cell Lung Carcinoma	[16]
Regorafenib + Irinotecan	DCJXAW3	Irinotecan	Colorectal Neoplasms	[17]
Regorafenib + Imatinib	DCQJHXB	Imatinib	Gastrointestinal Stromal Tumour	[18]
Regorafenib + Perindopril	DCR72MH	Perindopril	Metastatic Colorectal Cancer	[19]
Regorafenib + Capecitabine	DCZEKYJ	Capecitabine	Pancreatic Cancer	[20]
Ruxolitinib + Regorafenib	DCPHHE3	Ruxolitinib	Pancreatic Cancer	[20]
Ruxolitinib + Regorafenib	DC0WFUR	Ruxolitinib	CRC (Colorectal Cancer)	[21]
Sunitinib + Regorafenib	DCH61OA	Sunitinib	Gastrointestinal Stromal Tumors	[22]
Regorafenib + Irinotecan	DC1VG9T	Irinotecan	Metastatic Colorectal Cancer (mCRC)	[23]

References

• [1] Regorafenib FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891).
• [3] ClinicalTrials.gov (NCT02024607) A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
• [4] ClinicalTrials.gov (NCT01287598) BAY73-4506 Probe Substrate Study
• [5] ClinicalTrials.gov (NCT04008511) Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
• [6] ClinicalTrials.gov (NCT02085148) A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
• [7] ClinicalTrials.gov (NCT04625907) FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
• [8] ClinicalTrials.gov (NCT02386397) Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer
• [9] ClinicalTrials.gov (NCT05426811) Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
• [10] ClinicalTrials.gov (NCT02168777) Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
• [11] ClinicalTrials.gov (NCT02910843) Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer
• [12] ClinicalTrials.gov (NCT02106845) Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
• [13] ClinicalTrials.gov (NCT06095375) Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
• [14] ClinicalTrials.gov (NCT02164240) Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
• [15] ClinicalTrials.gov (NCT05113368) Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
• [16] ClinicalTrials.gov (NCT02795156) Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
• [17] ClinicalTrials.gov (NCT02096354) A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
• [18] ClinicalTrials.gov (NCT02365441) A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
• [19] ClinicalTrials.gov (NCT02651415) Phase II Study of Perindopril and Regorafenib in mCRC
• [20] ClinicalTrials.gov (NCT02955940) An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
• [21] ClinicalTrials.gov (NCT02119676) Study of Ruxolitinib in Colorectal Cancer Patients
• [22] ClinicalTrials.gov (NCT05366816) ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
• [23] ClinicalTrials.gov (NCT03829462) Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients